{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:59:58Z","timestamp":1712019598824},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,1]]},"DOI":"10.7759\/cureus.57368","type":"journal-article","created":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T07:41:01Z","timestamp":1711957261000},"source":"Crossref","is-referenced-by-count":0,"title":["Frequency of Complete Remission With R-CHOP Therapy in Patients With Diffuse Large B Cell Lymphoma"],"prefix":"10.7759","author":[{"given":"Sani U","family":"Hassan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shah","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahnoor","family":"Fakhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azaz","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fakeeda","family":"Durrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience","volume":"34","author":"Salles G","year":"2017","unstructured":"Salles G, Barrett M, Fo\u00e0 R, et al.. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017, 34:2232-2273. 10.1007\/s12325-017-0612-x","journal-title":"Adv Ther"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn LH","year":"2007","unstructured":"Sehn LH, Berry B, Chhanabhai M, et al.. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007, 109:1857-1861. 10.1182\/blood-2006-08-038257","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou Z","year":"2014","unstructured":"Zhou Z, Sehn LH, Rademaker AW, et al.. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014, 123:837-842. 10.1182\/blood-2013-09-524108","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14489","article-title":"Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of \u03b2(2)-microglobulin yields a more accurate GELTAMO-IPI","volume":"176","author":"Montalb\u00e1n C","year":"2017","unstructured":"Montalb\u00e1n C, D\u00edaz-L\u00f3pez A, Dlouhy I, et al.. Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of \u03b2(2)-microglobulin yields a more accurate GELTAMO-IPI. Br J Haematol. 2017, 176:918-928. 10.1111\/bjh.14489","journal-title":"Br J Haematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32526","article-title":"Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure","volume":"126","author":"Ayers EC","year":"2020","unstructured":"Ayers EC, Li S, Medeiros LJ, et al.. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. Cancer. 2020, 126:293-303. 10.1002\/cncr.32526","journal-title":"Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump M","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, et al.. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017, 130:1800-1808. 10.1182\/blood-2017-03-769620","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.130195","article-title":"Comparison of CAR-T19 and autologous stem cell transplantation for refractory\/relapsed non-Hodgkin's lymphoma","volume":"5","author":"Li C","year":"2019","unstructured":"Li C, Zhang Y, Zhang C, et al.. Comparison of CAR-T19 and autologous stem cell transplantation for refractory\/relapsed non-Hodgkin's lymphoma. JCI Insight. 2019, 5:e130195. 10.1172\/jci.insight.130195","journal-title":"JCI Insight"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-839217","article-title":"Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed\/refractory diffuse large B-cell lymphoma","volume":"132","author":"Chow VA","year":"2018","unstructured":"Chow VA, Shadman M, Gopal AK. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed\/refractory diffuse large B-cell lymphoma. Blood. 2018, 132:777-781. 10.1182\/blood-2018-04-839217","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/cells7100155","article-title":"Allogeneic CAR-T cells: more than ease of access?","volume":"7","author":"Graham C","year":"2018","unstructured":"Graham C, Jozwik A, Pepper A, Benjamin R. Allogeneic CAR-T cells: more than ease of access?. Cells. 2018, 7:155. 10.3390\/cells7100155","journal-title":"Cells"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S227477","article-title":"Apatinib in patients with relapsed or refractory diffuse large B cell lymphoma: a phase II, open-label, single-arm, prospective study","volume":"14","author":"Ma X","year":"2020","unstructured":"Ma X, Li L, Zhang L, et al.. Apatinib in patients with relapsed or refractory diffuse large B cell lymphoma: a phase II, open-label, single-arm, prospective study. Drug Des Devel Ther. 2020, 14:275-284. 10.2147\/DDDT.S227477","journal-title":"Drug Des Devel Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0286","article-title":"Phase I study of the investigational aurora A kinase inhibitor alisertib plus rituximab or rituximab\/vincristine in relapsed\/refractory aggressive B-cell lymphoma","volume":"24","author":"Kelly KR","year":"2018","unstructured":"Kelly KR, Friedberg JW, Park SI, et al.. Phase I study of the investigational aurora A kinase inhibitor alisertib plus rituximab or rituximab\/vincristine in relapsed\/refractory aggressive B-cell lymphoma. Clin Cancer Res. 2018, 24:6150-6159. 10.1158\/1078-0432.CCR-18-0286","journal-title":"Clin Cancer Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow SH","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, et al.. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016, 127:2375-2390. 10.1182\/blood-2016-01-643569","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2015.35.e449","article-title":"ABC, GCB, and double-hit diffuse large B-cell lymphoma: does subtype make a difference in therapy selection?","volume":"35","author":"Nowakowski GS","year":"2015","unstructured":"Nowakowski GS, Czuczman MS. ABC, GCB, and double-hit diffuse large B-cell lymphoma: does subtype make a difference in therapy selection?. Am Soc Clin Oncol Educ Book. 2015, 35:e449-e457. 10.14694\/EdBook_AM.2015.35.e449","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1047","article-title":"Cerdulatinib pharmacodynamics and relationships to tumor response following oral dosing in patients with relapsed\/refractory B-cell malignancies","volume":"25","author":"Coffey GP","year":"2019","unstructured":"Coffey GP, Feng J, Betz A, et al.. Cerdulatinib pharmacodynamics and relationships to tumor response following oral dosing in patients with relapsed\/refractory B-cell malignancies. Clin Cancer Res. 2019, 25:1174-1184. 10.1158\/1078-0432.CCR-18-1047","journal-title":"Clin Cancer Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study","volume":"37","author":"Ansell SM","year":"2019","unstructured":"Ansell SM, Minnema MC, Johnson P, et al.. Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study. J Clin Oncol. 2019, 37:481-489. 10.1200\/JCO.18.00766","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-867499","article-title":"Parsaclisib, a potent and highly selective PI3K\u03b4 inhibitor, in patients with relapsed or refractory B-cell malignancies","volume":"133","author":"Forero-Torres A","year":"2019","unstructured":"Forero-Torres A, Ramchandren R, Yacoub A, et al.. Parsaclisib, a potent and highly selective PI3K\u03b4 inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood. 2019, 133:1742-1752. 10.1182\/blood-2018-08-867499","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1706087","article-title":"Selinexor (KTP-330) - a selective inhibitor of nuclear export (SINE): anti-tumor activity in diffuse large B-cell lymphoma (DLBCL)","volume":"29","author":"Ben-Barouch S","year":"2020","unstructured":"Ben-Barouch S, Kuruvilla J. Selinexor (KTP-330) - a selective inhibitor of nuclear export (SINE): anti-tumor activity in diffuse large B-cell lymphoma (DLBCL). Expert Opin Investig Drugs. 2020, 29:15-21. 10.1080\/13543784.2020.1706087","journal-title":"Expert Opin Investig Drugs"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo E","year":"2011","unstructured":"Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011, 117:5019-5032. 10.1182\/blood-2011-01-293050","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson BD","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, et al.. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007, 25:579-586. 10.1200\/JCO.2006.09.2403","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0029","article-title":"NCCN guidelines insights: B-cell lymphomas, version 3.2019","volume":"17","author":"Zelenetz AD","year":"2019","unstructured":"Zelenetz AD, Gordon LI, Abramson JS, et al.. NCCN guidelines insights: B-cell lymphomas, version 3.2019. J Natl Compr Canc Netw. 2019, 17:650-661. 10.6004\/jnccn.2019.0029","journal-title":"J Natl Compr Canc Netw"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2017.09.006","article-title":"Diffuse large B-cell lymphoma","volume":"50","author":"Li S","year":"2018","unstructured":"Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018, 50:74-87. 10.1016\/j.pathol.2017.09.006","journal-title":"Pathology"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-04862-4","article-title":"A new nomogram for assessing complete response (CR) in gastric diffuse large B-cell lymphoma (DLBCL) patients after chemotherapy","volume":"149","author":"Wang P","year":"2023","unstructured":"Wang P, Chen K, Wang J, Ni Z, Shang N, Meng W. A new nomogram for assessing complete response (CR) in gastric diffuse large B-cell lymphoma (DLBCL) patients after chemotherapy. J Cancer Res Clin Oncol. 2023, 149:9757-9765. 10.1007\/s00432-023-04862-4","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-021-00208-3","article-title":"Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review","volume":"10","author":"Decruyenaere P","year":"2021","unstructured":"Decruyenaere P, Offner F, Vandesompele J. Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review. Exp Hematol Oncol. 2021, 10:13. 10.1186\/s40164-021-00208-3","journal-title":"Exp Hematol Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006415","article-title":"Risk profiling of patients with relapsed\/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA","volume":"6","author":"Herrera AF","year":"2022","unstructured":"Herrera AF, Tracy S, Croft B, et al.. Risk profiling of patients with relapsed\/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA. Blood Adv. 2022, 6:1651-1660. 10.1182\/bloodadvances.2021006415","journal-title":"Blood Adv"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/237359-frequency-of-complete-remission-with-r-chop-therapy-in-patients-with-diffuse-large-b-cell-lymphoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T07:41:09Z","timestamp":1711957269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/237359-frequency-of-complete-remission-with-r-chop-therapy-in-patients-with-diffuse-large-b-cell-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.57368","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,1]]}}}